MARKET

KTRA

KTRA

Kintara Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.2550
-0.0230
-8.27%
Pre Market: 0.2399 -0.0151 -5.92% 09:23 07/05 EDT
OPEN
0.2750
PREV CLOSE
0.2780
HIGH
0.2879
LOW
0.2500
VOLUME
13.32K
TURNOVER
--
52 WEEK HIGH
2.850
52 WEEK LOW
0.1406
MARKET CAP
16.71M
P/E (TTM)
-0.3728
1D
5D
1M
3M
1Y
5Y
44 Stocks Moving In Thursday's Mid-Day Session: F-star Therapeutics, Revlon And More
 Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
Benzinga · 06/23 16:29
Kintara Therapeutics to Present at the Alliance Global Partners Summer Healthcare Conference
Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that President and CEO Robert E. Hoffman will present a corporate overview a...
PR Newswire · 06/21 12:00
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 06/16 12:11
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 06/16 11:34
27 Stocks Moving in Thursday's Pre-Market Session
Gainers Heart Test Laboratories, Inc. (NASDAQ: HSCS) rose 92.9% to $3.28 in pre-market trading following’s Wednesday IPO.
Benzinga · 06/16 10:58
Mid-Afternoon Market Update: Dow Jumps Over 300 Points; Fed Boosts Interest Rates by 0.75%
U.S. stocks traded higher toward the end of trading, after the Federal Reserve raised interest rates by 0.75%.
Benzinga · 06/15 19:07
Mid-Day Market Update: Nasdaq Rises 200 Points; 180 Life Sciences Shares Plummet
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Wednesday.
Benzinga · 06/15 16:20
55 Stocks Moving In Wednesday's Mid-Day Session
Gainers Sidus Space, Inc. (NASDAQ: SIDU) shares surged 92.4% to $2.77 after the company announced it is part of Collins Aerospace team which was awarded NASA's Exploration Extravehicular Activity services contract with a potential value of $3.5 billion.
Benzinga · 06/15 16:14
More
No Data
Learn about the latest financial forecast of KTRA. Analyze the recent business situations of Kintara Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
66.67%Buy
33.33%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average KTRA stock price target is 3.167 with a high estimate of 5.00 and a low estimate of 1.500.
High5.00
Average3.167
Low1.500
Current 0.2571
EPS
Actual
Estimate
-0.14-0.10-0.07-0.03
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 33
Institutional Holdings: 3.51M
% Owned: 5.35%
Shares Outstanding: 65.53M
TypeInstitutionsShares
Increased
3
97.90K
New
5
32.29K
Decreased
4
179.55K
Sold Out
6
392.10K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.38%
Pharmaceuticals & Medical Research
-0.78%
Key Executives
Chairman/President/Chief Executive Officer/Director
Robert Hoffman
Chief Financial Officer
Scott Praill
Senior Vice President
John Liatos
Chief Scientific Officer
Dennis Brown
Vice President - Research & Development
Steven Rychnovsky
Independent Director
Laura Johnson
Independent Director
Tamara Seymour
Independent Director
Robert Toth
No Data
No Data
About KTRA
Kintara Therapeutics, Inc. is a clinical-stage, biopharmaceutical company focused on the development and commercialization of new cancer therapies. The Company is developing two late-stage, Phase III-ready therapeutics. The Company's two lead product candidates are VAL-083 and REM-001. VAL- 083 is a validated, Deoxyribonucleic acid (DNA)-targeting agent, for the treatment of drug-resistant solid tumors such as glioblastoma multiforme (GBM) and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). REM-001 is a late-stage photodynamic therapy (PDT) for the treatment of cutaneous metastatic breast cancer (CMBC). The Company is carrying out various clinical trials on brain tumor and solid tumor.

Webull offers kinds of Kintara Therapeutics Inc stock information, including NASDAQ:KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.